Martínez, Alfredo P García, Gabriel Ridruejo, Ezequiel Culasso, Andrés Ca Pérez, Paula S Pereson, Matías J Neukam, Karin Flichman, Diego Di Lello, Federico A
Published in
Journal of medical virology
Direct acting antiviral (DAA) therapy against hepatitis C virus (HCV) increases sustained virologic response rates. Nevertheless, drug resistance has occasionally been associated with failure to DAA. However, the information about the prevalence of NS5A and NS5B resistance-associated substitutions (RASs) in Argentina is very scarce. In this study, ...
Martinello, Marianne Orkin, Chloe Cooke, Graham Bhagani, Sanjay Gane, Edward Kulasegaram, Ranjababu Shaw, David Tu, Elise Petoumenos, Kathy Marks, Philippa
...
Published in
Hepatology (Baltimore, Md.)
Among treatment-naïve individuals with chronic HCV infection and without cirrhosis, glecaprevir-pibrentasvir for eight weeks is recommended. The aim of this analysis was to evaluate the efficacy of glecaprevir-pibrentasvir for six weeks in people with acute and recent HCV infection. In this open-label single-arm multicentre international pilot stud...
Persico, Marcello Aglitti, Andrea Milella, Michele Coppola, Carmine Messina, Vincenzo Claar, Ernesto Gentile, Ivan Sogari, Fernando Pierri, Paola Surace, Lorenzo A
...
Published in
Liver international : official journal of the International Association for the Study of the Liver
It is paramount to identify predictors of treatment failure with direct antiviral agents in 'field-practice' patients, including people who inject drugs (PWID). Data on the efficacy of glecaprevir/pibrentasvir (GLE/PIB) in a field-practice scenario are scant. The multicentre MISTRAL study enrolled 1177 patients, including PWID, to assess real-life ...
Wu, Ruihong Geng, Dongfeng Chi, Xiumei Wang, Xiaomei Gao, Xiuzhu Xu, Hongqin Shi, Ying Guan, Yazhe Wang, Yang Jin, Jinglan
...
Published in
Infection and drug resistance
Direct-acting antivirals (DAA) facing resistance continue to be used in some areas worldwide. Thus, identifying hepatitis C virus (HCV) genotypes/subtypes and loci with certain prevalent resistance-associated substitutions (RASs) deserves attention. We investigated the global and regional frequencies of naturally occurring RASs among all confirmed ...
Belperio, Pamela S Shahoumian, Troy A Loomis, Timothy P Backus, Lisa I
Published in
Journal of viral hepatitis
Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) provides a needed hepatitis C virus (HCV) antiviral option for direct-acting antiviral (DAA)-experienced patients. We evaluated the effectiveness of SOF/VEL/VOX for 12 weeks in DAA-experienced patients with genotype 1-4 treated in clinical practice. In this observational cohort analysis from the Vet...
Bajis, Sahar Grebely, Jason Cooper, Lucy Smith, Julie Owen, Greg Chudleigh, Alan Hajarizadeh, Behzad Martinello, Marianne Adey, Sara Read, Phillip
...
Published in
Journal of viral hepatitis
People who are homeless have increased hepatitis C virus (HCV) infection risk, and are less likely to access primary healthcare. We aimed to evaluate HCV RNA prevalence, liver disease burden, linkage to care and treatment uptake and outcomes among people attending a homelessness service in Sydney. Participants were enrolled in an observational coho...
Dvory-Sobol, Hadas Han, Bin Lu, Julia Yu, Mei Beran, Rudolf K Cheng, Guofeng Martin, Ross Svarovskaia, Evguenia Mo, Hongmei
Published in
Journal of viral hepatitis
Velpatasvir is a pan-genotypic hepatitis C virus (HCV) NS5A inhibitor, which is used with sofosbuvir for treatment of infection with HCV genotypes 1-6. In vitro resistance studies were performed to characterize NS5A changes that might confer reduced velpatasvir susceptibility in vivo. Resistance selection studies using HCV replicon cells for subtyp...
Koren, David E Zuckerman, Autumn Teply, Robyn Nabulsi, Nadia A Lee, Todd A Martin, Michelle T
Published in
Open Forum Infectious Diseases
A clinical pharmacist-driven model for hepatitis C virus treatment at four open health-systems yielded sustained virologic response rates comparable to published rates of specialists and non-specialists. This model can be implemented to assist with national hepatitis C virus elimination goals.
Tow, Clara Y Reinus, John F
Published in
Journal of investigative medicine high impact case reports
In this era of direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection, treated patients have extremely high rates of sustained virologic response to short courses of therapy regardless of stage of fibrosis. Treatment failure is uncommon and often attributed to medication noncompliance or viral resistance to drug. This r...
Bixby, Alexandra L Fitzgerald, Linda Leek, Rachael Mellinger, Jessica Sharma, Pratima Tischer, Sarah
Published in
Transplant infectious disease : an official journal of the Transplantation Society
Direct-acting antivirals (DAAs) have transformed hepatitis C virus (HCV) management post-liver transplant. As HCV clears during DAA treatment, hepatic metabolism improves, resulting in decreased tacrolimus concentrations that may require dose adjustment. The purpose of this study was to determine appropriate management of immunosuppression in liver...
